Surprisingly, IL-5 targeting biologics (mepolizumab, reslizumab) and even complete eosinophil depletion with benralizumab (anti- IL5Rα; MESSINA, NCT04543409) or lirentilimab (anti-Siglec-8; KRYPTOS, NCT04322708) in the esophagi of patients with EoE did not lead to complete symptom improvement and clinical remission (37, 38). Here, IL5 is linked to eosinophilic esophagitis.